Finance

Lists
AGMB:NASDAQ
Agomab Therapeutics NV
$6.77
+0.74%
(+0.050) 1D
Nov 3, 1:26:53 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGMB...
Open
$6.67
High
$7.16
Low
$6.67
Mkt. cap
333.41M
Avg. vol.
141.01K
Volume
23.18K
52-wk high
$17.82
52-wk low
$6.55
No. of employees
62
Open
$6.67
High
$7.16
Low
$6.67
Mkt. cap
333.41M
Avg. vol.
141.01K
Volume
23.18K
52-wk high
$17.82
52-wk low
$6.55
No. of employees
62
News stories
From web sources and news partners
About Agomab Therapeutics NV
CEO-
Employees62
Founded2017
Headquarters-
SectorPharmaceutical industry
Websiteagomab.com
Analyst ratings
Based on 6 analysts giving stock ratings to AGMB in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AGMB in the last 3 months.
Highest
Current $6.77
$60.00 (+786.26%)
Average
$35.20 (+419.94%)
Lowest
$17.00 (+151.11%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Ulz
Morgan Stanley
Buy
Reiterated
$28.00
+313.6%
11/02/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$35.00
+417%
10/20/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$28.00
+313.6%
10/19/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$60.00
+786.3%
10/14/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$36.00
+431.8%
10/02/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
09/14/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
$17.00
+151.1%
08/19/2026
William Wood
B. Riley Securities
Buy
Initiated
$34.00
+402.2%
07/23/2026
Thomas Smith
Leerink Partners
Buy
Initiated
$36.00
+431.8%
03/03/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Jun 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
11.01M
13.86M
11.48M
11.48M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.34M
3.17M
6.09M
6.09M
Operating expense
13.70M
16.53M
17.03M
17.03M
Total operating expenses
13.70M
16.53M
17.03M
17.03M
Operating income
-13.70M
-16.53M
-17.03M
-17.03M
Other non operating income
-128.00K
-1.54M
-219.00K
-219.00K
EBT including unusual items
-13.43M
-17.40M
-15.49M
-15.49M
EBT excluding unusual items
-13.43M
-17.40M
-15.49M
-15.49M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-656.00K
-506.00K
-539.50K
-539.50K
Net income
-13.43M
-17.40M
-15.49M
-15.49M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
427.50K
720.00K
1.87M
1.87M
Interest expense
-37.50K
-
-107.50K
-107.50K
Net interest expenses
390.00K
720.00K
1.76M
1.76M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.60M
-16.51M
-16.94M
-16.94M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps